{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:32:05Z","timestamp":1788201125138,"version":"build-2803163510"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Soc Psychiatry"],"abstract":"<jats:p>Psychomotor agitation is a common mental emergency that requires immediate, safe treatment. Intramuscular haloperidol is frequently used; however oral alternatives may be safer and more tolerated. In many low- and middle-income settings, resource constraints, cultural norms, and emergency department coercion shape agitation prescribing. This study compared the efficacy and safety of oral risperidone plus clonazepam versus injectable haloperidol for psychomotor agitation in primary psychotic patients. In this single-blind, randomized comparative trial, 260 patients (mean age 32.38; 95% CI [31.13\u201333.64], 119 males and 141 females) with severe psychomotor agitation in a general hospital emergency room were randomly assigned oral risperidone 3\u2009mg plus clonazepam 3\u2009mg (RC) or intramuscular haloperidol 5 mg. Behavioral Activity Rating Scale (BARS) agitation was measured at 30, 1, and 2\u2009hr. The primary outcome was the percentage of patients reported as tranquil (BARS = 4) or tranquil\/asleep (BARS = 2\u20134) at all time points, with an equivalency margin of \u00b120%. Secondary outcomes included tranquil\/tranquil or asleep after 2\u2009hr, restraint use, adverse effects (during the 2\u2009hr of assessment), and necessity of additional medication after 1\u2009hr. RC and IH were equally tranquil or sleeping at all time points for primary outcomes (adjusted ARR 9 percentage points, 95% CI \u22121.8 to +19.8). Neither tranquility at 2\u2009hr nor extra medication were equal for secondary outcomes (adjusted ARR 15 p.p., 95% CI [1.35, 28.65]). At 2\u2009hr, tranquil or asleep, restraint utilization, and side effects were equivalent. In conclusion, besides oral risperidone plus clonazepam met the prespecified criterion for equivalence to intramuscular haloperidol for the primary composite outcomes of maintaining tranquility or tranquility\/asleep at all time-points during the 2-hr observation period, the equivalence was not demonstrated for all secondary outcomes. The oral regimen was associated with a greater need for additional medication. Therefore, the two regimens should not be considered fully interchangeable in all emergency presentations. We found that oral techniques may enable more humane, less invasive, and culturally acceptable emergency care in LMICs due to the social burden of injectable medication, which typically requires restraint.<\/jats:p>","DOI":"10.1177\/00207640261478551","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T03:50:52Z","timestamp":1788061852000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Less Invasive Rapid Tranquilization in LMIC Emergency Settings: Comparison of Oral Risperidone Plus Clonazepam Versus Intramuscular Haloperidol in a Randomized Trial"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-8515","authenticated-orcid":false,"given":"Leonardo","family":"Balda\u00e7ara","sequence":"first","affiliation":[{"name":"Hospital Geral de Palmas, Tocantins, TO, Brazil"},{"name":"Universidade Federal do Tocantins, Palmas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4130-1438","authenticated-orcid":false,"given":"Railson Alves","family":"de Freitas","sequence":"additional","affiliation":[{"name":"Hospital Geral de Palmas, Tocantins, TO, Brazil"},{"name":"Universidade Federal do Tocantins, Palmas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-0449","authenticated-orcid":false,"given":"Acioly Luiz Tavares","family":"Lacerda","sequence":"additional","affiliation":[{"name":"PRODAF\u2014Programa de Transtornos Afetivos, Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, Brazil"},{"name":"BR Trials\u2014Clinical Research, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-5101","authenticated-orcid":false,"given":"Cintia de Azevedo Marques","family":"P\u00e9rico","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o da Faculdade de Medicina do ABC, Santo Andr\u00e9, S\u00e3o Paulo, Brazil"},{"name":"Facili Pesquisa Cl\u00ednica, S\u00e3o Bernardo do Campo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2018-0177"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2018-0163"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.25118\/2763-9037.2021.v11.13"},{"key":"e_1_3_3_5_1","article-title":"Brazilian Psychiatric Association treatment guidelines for generalized anxiety disorder: Perspectives on pharmacological and psychotherapeutic approaches","volume":"46","author":"Balda\u00e7ara L.","year":"2024","unstructured":"Balda\u00e7ara L., Paschoal A. B., Pinto A. F., Loureiro F. F., Antonio L. A. V. G., Veiga D. de L., Almeida T. M., dos Santos D. C., Malloy-Diniz L. F., de Mello M. F., de Mello A. F., Sanches M., Gandarela L. M., Bernik M. A., Nardi A. E., da Silva A. G., Uchida R. R. (2024). Brazilian Psychiatric Association treatment guidelines for generalized anxiety disorder: Perspectives on pharmacological and psychotherapeutic approaches. Brazilian Journal of Psychiatry, 46, Article e20233235. https:\/\/doi.org\/10.47626\/1516-4446-2023-3235","journal-title":"Brazilian Journal of Psychiatry"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psycom.2024.100168"},{"issue":"1","key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.25118\/2763-9037.2021.v11.6","article-title":"Considera\u00e7\u00f5es iniciais","volume":"11","author":"Balda\u00e7ara L.","year":"2021","unstructured":"Balda\u00e7ara L., Pinto F. I., Leite V. (2021). Considera\u00e7\u00f5es iniciais. Debates Em Psiquiatria, 11(1), 6\u20137.","journal-title":"Debates Em Psiquiatria"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.25118\/2763-9037.2021.v11.11"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-44462011000100008"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-6757(97)90119-4"},{"issue":"4","key":"e_1_3_3_11_1","article-title":"A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.","volume":"38","author":"Chouinard G.","year":"1993","unstructured":"Chouinard G., Annable L., Turnier L., Holobow N., Szkrumelak N. (1993). A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 38(Suppl 4), S114\u2013S121.","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60873-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0315"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00573"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.11.011"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2535"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834fc431"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2015.1132007"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Gillies D. Sampson S. Beck A. Rathbone J. (2013). Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews 2013(4) Article CD003079. https:\/\/doi.org\/10.1002\/14651858.CD003079.pub3","DOI":"10.1002\/14651858.CD003079.pub3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181db8715"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39339.448819.AE"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2001000600005"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Leucht C. Kitzmantel M. Kane J. (2008). Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 23(1) Article CD004278. https:\/\/doi.org\/10.1002\/14651858.CD004278.pub2","DOI":"10.1002\/14651858.CD004278.pub2"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000315437"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1854-0185"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.5.803"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2013.1316598"},{"key":"e_1_3_3_28_1","article-title":"Translation, cross-cultural adaptation, and validation of the Behavioral Activity Rating Scale (BARS) for the Brazilian population","volume":"45","author":"Pereira L. A.","year":"2023","unstructured":"Pereira L. A., da Silva A. G., Hemanny C., de Jesus R., Moromizato M., Vieira T., Souza M., Lima M. G., Balda\u00e7ara L. (2023). Translation, cross-cultural adaptation, and validation of the Behavioral Activity Rating Scale (BARS) for the Brazilian population. Trends in Psychiatry and Psychotherapy, 45, Article e20210310\ufeff. https:\/\/doi.org\/10.47626\/2237-6089-2021-0310","journal-title":"Trends in Psychiatry and Psychotherapy"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2021.110326"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39341.608519.BE"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.10.010"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-89102000000500006"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19094945"},{"issue":"1","key":"e_1_3_3_34_1","article-title":"Treatment for amphetamine psychosis","volume":"2009","author":"Shoptaw S. J.","year":"2009","unstructured":"Shoptaw S. J., Kao U., Ling W. (2009). Treatment for amphetamine psychosis. Cochrane Database of Systematic Reviews, 2009(1), CD003026.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000787"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0614"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Tardy M. Huhn M. Kissling W. (2014). Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 9(7) Article CD009268. https:\/\/doi.org\/10.1002\/14651858.CD009268.pub2.","DOI":"10.1002\/14651858.CD009268.pub2"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7417.708"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06426-3"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200603000-00005"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000050"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0374-6"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2011.9.6866"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13117"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2022-300546"}],"container-title":["International Journal of Social Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00207640261478551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00207640261478551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00207640261478551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:51:03Z","timestamp":1788198663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00207640261478551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":44,"alternative-id":["10.1177\/00207640261478551"],"URL":"https:\/\/doi.org\/10.1177\/00207640261478551","relation":{},"ISSN":["0020-7640","1741-2854"],"issn-type":[{"value":"0020-7640","type":"print"},{"value":"1741-2854","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"article-number":"00207640261478551"}}